MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
TherapeuticsMD EBITDA 2011-2026 | TXMD
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA TherapeuticsMD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.6 M | 2.38 M | -78.8 M | -154 M | -151 M | -130 M | -77.4 M | -90.1 M | -85.1 M | -54 M | -25.8 M | -16.1 M | -5.37 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.38 M | -154 M | -67.1 M |
Quarterly EBITDA TherapeuticsMD
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -766 K | -599 K | -776 K | - | -1.04 M | -2.61 M | -1.01 M | - | - | -2.34 M | -2.64 M | - | -14.3 M | -14.7 M | -17.5 M | -35.4 M | -36.8 M | -33.1 M | -28.3 M | -34.6 M | -24.7 M | -44.8 M | -49.9 M | - | -26.9 M | -41.5 M | -38 M | - | -34.3 M | -33 M | -24.7 M | - | -14.8 M | -19.8 M | -21.2 M | - | -25.1 M | -21.2 M | -21 M | - | -19.5 M | -27.2 M | -20.9 M | - | -17.8 M | -10.9 M | -8.94 M | - | -7.2 M | -5.61 M | -4.93 M | 28.8 K | -3.9 M | -3.96 M | -2.85 M | - | -1.4 M | -1.02 M | -758 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.8 K | -49.9 M | -17.1 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Drug manufacturers industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
6.82 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-40 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-23.6 M | - | 0.86 % | $ 117 M | USA |
 |
China Pharma Holdings
CPHI
|
-1.97 M | $ 0.57 | -9.62 % | $ 9.95 M |  China |
 |
Eagle Pharmaceuticals
EGRX
|
81.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.32 | 0.3 % | $ 86.3 M |  Canada |
 |
Catalent
CTLT
|
-260 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-65.5 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-39.7 M | - | - | $ 2.06 B |  France |
 |
Cronos Group
CRON
|
-176 M | $ 2.58 | 2.38 % | $ 1.34 B | Canada |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-601 M | $ 8.01 | -0.5 % | $ 410 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
3.06 M | $ 3.13 | 2.62 % | $ 44 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-100 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
2.23 B | $ 4.99 | -2.25 % | $ 1.82 B | Canada |
 |
Pacira BioSciences
PCRX
|
5.41 M | $ 23.2 | 2.43 % | $ 1.07 B | USA |
 |
Harrow Health
HROW
|
31.8 M | $ 35.2 | 3.53 % | $ 1.29 B | USA |
 |
PetIQ
PETQ
|
81.6 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-22.3 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-40.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Perrigo Company plc
PRGO
|
-785 M | $ 9.64 | 0.73 % | $ 1.34 B | USA |
 |
ProPhase Labs
PRPH
|
28.3 M | - | - | $ 5.07 M | USA |
 |
Evolus
EOLS
|
-25.2 M | $ 4.43 | -5.34 % | $ 286 M | USA |
 |
Radius Health
RDUS
|
-53.2 M | - | - | $ 1.42 B | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.37 | 0.74 % | $ 3.37 M | Canada |
 |
Rockwell Medical
RMTI
|
-5.23 M | $ 1.03 | 0.98 % | $ 24 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 6.1 | 4.1 % | $ 241 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.34 | -1.47 % | $ 402 M | Canada |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.9 | 2.8 % | $ 44.9 M | USA |
 |
Jupiter Wellness
JUPW
|
429 K | - | - | $ 33.6 M | USA |
 |
Solid Biosciences
SLDB
|
-178 M | $ 6.68 | -6.44 % | $ 585 M | USA |
 |
Lannett Company
LCI
|
-142 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.57 M | $ 2.34 | -8.24 % | $ 2.9 M | USA |
 |
Organogenesis Holdings
ORGO
|
12.3 M | $ 2.41 | -2.43 % | $ 317 M | USA |
 |
Canopy Growth Corporation
CGC
|
-95.6 M | $ 0.96 | -0.87 % | $ 103 M | Canada |
 |
Tilray
TLRY
|
-1.37 B | $ 6.66 | 3.26 % | $ 4.12 B | Canada |
 |
Assertio Holdings
ASRT
|
8.47 M | $ 16.51 | 17.93 % | $ 106 M | USA |
 |
Recro Pharma
REPH
|
4.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Veru
VERU
|
-36.6 M | $ 2.29 | -0.43 % | $ 309 M | USA |
 |
Viatris
VTRS
|
3.51 B | $ 13.36 | 0.53 % | $ 16 B | USA |
 |
cbdMD
YCBD
|
-2.86 M | $ 0.77 | 1.06 % | $ 3.32 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |